We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Brain Cancer

Journal Scan / Research · December 01, 2020

Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment

Cancer Research

 

Additional Info

Cancer Research
Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment
Cancer Res 2020 Nov 15;80(22)5098-5108, E Subramani, M Radoul, C Najac, G Batsios, AR Molloy, D Hong, AM Gillespie, RD Santos, P Viswanath, JF Costello, RO Pieper, SM Ronen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading